Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rudiger Hehlmann"'
Autor:
Tariq I. Mughal, Alessandro M. Vannucchi, Simona Soverini, Alexandra Bazeos, Raoul Tibes, Giuseppe Saglio, Omar Abdel-Wahab, Animesh Pardanani, Rudiger Hehlmann, Tiziano Barbui, Richard Van Etten, Ayalew Tefferi, John M. Goldman
Publikováno v:
Haematologica, Vol 99, Iss 5 (2014)
Externí odkaz:
https://doaj.org/article/7d84a65074b544c5a899035fcac4e700
Autor:
Irina Korenkova, Menachem Bitan, Sergiy Klymenko, Oleksandr Lysytsia, Jan Zaucha, Joannis Mytilineos, Torsten Haferlach, Andreas Hochaus, Mats Heyman, Francois Guilhot, Natascha Bolanos, Roman Kuts, HIldegard Greinix, Mickey B C Koh, Susan Landgraf, Rudiger Hehlmann, Mahmoud Aljurf, Anna Sureda, Damiano Rondelli, Dietger Niederwieser
Publikováno v:
Transplantation and Cellular Therapy. 29:S301-S302
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d6ca0e62ff0d861becdf2cfc7d46ed2
https://doi.org/10.1016/s2666-6367(23)00467-0
https://doi.org/10.1016/s2666-6367(23)00467-0
Autor:
Dietger Niederwieser, Dirk Hasenclever, Wolfgang Berdel, Bart J. Biemond, Haifa Al-Ali, Yves Chalandon, Michel van Gelder, Christian Junghanß, Gösta Gahrton, Mathias Hänel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jacob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Leo F. Verdonck, Vladan Vucinic, Bob Löwenberg, Jan Cornelissen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged
Externí odkaz:
https://doaj.org/article/e24e854d3915489f8bfdf3f02374efc6
Autor:
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela M Baerlocher, Jiri Mayer, Tim H Brümmendorf, Paul La Rosee, Dominik Heim, Stefan W Krause, Philipp Le Coutre, Christian Fabisch, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hänel, Frank Stegelmann, Georg-Nikolaus Franke, Markus Radsak, Volker Kunzmann, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Thomas Ernst, Markus Pfirrmann
Publikováno v:
HemaSphere, Vol 7, p e4695659 (2023)
Externí odkaz:
https://doaj.org/article/058c2d6abf82442594508bb351be8d6c
Autor:
William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti
Publikováno v:
JNCI Journal of the National Cancer Institute
© The Author 2016. Published by Oxford University Press.Background: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42698558a7334d55ab20503cad057adb
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304522
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304522
Autor:
European LeukemiaNet, Francois Guilhot, Rudiger Hehlmann, Joerg Hasford, Philipp le Coutre, Josef Thaler, Gianantonio Rosti, Francisco Cervantes, Jesper Stentoft, Gert Ossenkoppele, Kimmo Porkka, Philippe Rousselot, Franck Nicolini, Arnon Nagler, Markus Pfirmann, Florence Tartarin, Joelle Guilhot
Publikováno v:
Blood. 108:4764-4764
The purpose of the registry is to collect existing cases of pts who failed imatinib therapy. Since the drug has been registered most of information on safety and efficacy were collected through clinical trials. Thus the true rate of failure is curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26717eea7e674cc144d82a0aded4ee32
https://doi.org/10.1182/blood.v108.11.4764.4764
https://doi.org/10.1182/blood.v108.11.4764.4764
Autor:
Rüdiger Hehlmann
Publikováno v:
HemaSphere, Vol 4, Iss 5, p e468 (2020)
Abstract. New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, doe
Externí odkaz:
https://doaj.org/article/3b17e274ad014dcba8e2f79506084dbd
Autor:
Rüdiger Hehlmann
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss , Pp 9- (2020)
Externí odkaz:
https://doaj.org/article/946a484fa94b4130ae54cd229b260c55
Autor:
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Michael Lauseker, Stefan W. Krause, Hans-Jochem Kolb, Dieter Kurt Hossfeld, Christoph Nerl, Gabriela M. Baerlocher, Dominik Heim, Tim H Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Leopold Balleisen, Maria-Elisabeth Goebeler, Mathias Hänel, Anthony Ho, Jolanta Dengler, Christiane Falge, Robert Möhle, Stephan Kremers, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius F. Waller, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiri Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, Winfried Gassmann, Michael Schenk, Peter Brossart, Thomas Wündisch, Thomas Geer, Stephan Bildat, Erhardt Schäfer, Joerg Hasford, Rüdiger Hehlmann, Markus Pfirrmann
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep mo
Externí odkaz:
https://doaj.org/article/8f2e3c990dda4c23bf1aba8a1a3b48ba
Autor:
Rüdiger Hehlmann
Publikováno v:
Haematologica, Vol 102, Iss 3 (2017)
Externí odkaz:
https://doaj.org/article/6bb8c7cb88ad4829b55b396cd5e5eb9b